DeepMed Research

Inozyme Pharma

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 2016-01-01

Employees: 59

Market Cap: $367.7M

Website: http://www.inozyme.com

Introduction: Inozyme Pharma, Inc. is a clinical-stage rare disease biopharmaceutical company. It engages in the business of developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue, and skeleton. The company was founded by Axel Bolte, Joseph P. Schlessinger, and Demetrios T. Braddock in September 2015 and is headquartered in Boston, MA.

Clinical Trials

The ENABLE Study: Safety and Efficacy Study of INZ-701 in Patients With ENPP1 Deficiency

Phase 2

Withdrawn

Conditions: Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency
Autosomal Recessive Hypophosphatemic Rickets
Generalized Arterial Calcification of Infancy 1

Interventions: Drug: INZ-701

First Posted Date: 2024-12-18

Last Posted Date: 2025-05-01

Lead Sponsor: Inozyme Pharma

Target Recruit Count: 40

Registration Number: NCT06739980

ADAPT Study: Long-term Safety Study of INZ-701 in Patients With ENPP1 Deficiency and ABCC6 Deficiency

Phase 2

Recruiting

Conditions: Gene Mutations
Pseudoxanthoma Elasticum
Arterial Calcification
Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency
Autosomal Recessive Hypophosphatemic Rickets Type 2

Interventions: Drug: INZ-701

First Posted Date: 2024-06-17

Last Posted Date: 2024-11-28

Lead Sponsor: Inozyme Pharma

Target Recruit Count: 200

Registration Number: NCT06462547

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇺🇸
Clinilabs Drug Development Corporation, Eatontown, New Jersey, United States
🇫🇷
Necker-Enfants Malades Hospital, Paris, France

and more 2 locations

PROPEL - A Prospective Observational Patient Registry to Evaluate ENPP1 and ABCC6 Deficiency

Recruiting

Conditions: Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 Deficiency
ATP-Binding Cassette Subfamily C Member 6 Deficiency

First Posted Date: 2024-03-08

Last Posted Date: 2025-02-27

Lead Sponsor: Inozyme Pharma

Target Recruit Count: 1000

Registration Number: NCT06302439

Locations: 🇺🇸
Ann and Robert H. Lurie Children's Hospital, Chicago, Illinois, United States
🇺🇸
Boston Children's Hospital, Boston, Massachusetts, United States
🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

and more 6 locations

The SEAPORT 1 Study: Evaluation of the Safety and Tolerability of INZ-701 in Adults With End-Stage Kidney Disease Undergoing Hemodialysis

Phase 1

Completed

Conditions: Calciphylaxis

Interventions: Drug: INZ-701

First Posted Date: 2024-02-28

Last Posted Date: 2025-02-05

Lead Sponsor: Inozyme Pharma

Target Recruit Count: 11

Registration Number: NCT06283589

Locations: 🇺🇸
South Florida Nephrology Research, Coral Springs, Florida, United States
🇺🇸
Elixia Health, Hollywood, Florida, United States

The ENERGY 3 Study: Evaluation of Efficacy and Safety of INZ-701 in Children With ENPP1 Deficiency

Phase 3

Active, not recruiting

Conditions: Ectonucleotide Pyrophosphatase/Phosphodiesterase1 Deficiency
Generalized Arterial Calcification of Infancy
Autosomal Recessive Hypophosphatemic Rickets

Interventions: Drug: Control Arm (Conventional Therapy)
Drug: INZ-701

First Posted Date: 2023-09-21

Last Posted Date: 2025-05-01

Lead Sponsor: Inozyme Pharma

Target Recruit Count: 27

Registration Number: NCT06046820

Locations: 🇺🇸
Children's Hospital of Colorado, Aurora, Colorado, United States
🇦🇺
Queensland Children's Hospital, South Brisbane, Australia
🇸🇦
King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia

and more 12 locations

The ENERGY Study: Evaluation of Safety and Tolerability of INZ-701 in Infants With ENPP1 Deficiency or ABCC6 Deficiency

Phase 1

Recruiting

Conditions: Autosomal Recessive Hypophosphatemic Rickets
Pseudoxanthoma Elasticum
Generalized Arterial Calcification of Infancy
Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency
ATP-Binding Cassette Subfamily C Member 6 Deficiency

Interventions: Drug: INZ-701

First Posted Date: 2023-02-17

Last Posted Date: 2025-02-07

Lead Sponsor: Inozyme Pharma

Target Recruit Count: 16

Registration Number: NCT05734196

Locations: 🇺🇸
Rady Children's Hospital, San Diego, California, United States
🇺🇸
Boston Children's Hospital, Boston, Massachusetts, United States
🇺🇸
Nationwide Children's Hospital, Columbus, Ohio, United States

and more 4 locations

Natural History Study of ENPP1 Deficiency and and the Early-onset Form of ABCC6 Deficiency

Conditions: Generalized Arterial Calcification of Infancy
Autosomal Recessive Hypophosphatemic Rickets
ATP-Binding Cassette Subfamily C Member 6 Deficiency
Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency

First Posted Date: 2021-09-20

Last Posted Date: 2022-01-27

Lead Sponsor: Inozyme Pharma

Target Recruit Count: 30

Registration Number: NCT05050669

Locations: 🇺🇸
Boston Children's Hospital, Boston, Massachusetts, United States
🇺🇸
CHOP - Robers Center for Pediatric Research, Philadelphia, Pennsylvania, United States
🇺🇸
Cook Children's Hospital, Fort Worth, Texas, United States

and more 2 locations

Evaluation of Safety, Tolerability, and Efficacy of INZ-701 in Adults With ABCC6 Deficiency Causing PXE

Phase 1

Completed

Conditions: Pseudoxanthoma Elasticum
ATP-Binding Cassette Subfamily C Member 6 Deficiency
Generalized Arterial Calcification of Infancy

Interventions: Drug: INZ-701

First Posted Date: 2021-09-01

Last Posted Date: 2025-02-05

Lead Sponsor: Inozyme Pharma

Target Recruit Count: 10

Registration Number: NCT05030831

Locations: 🇺🇸
Clinilabs, Eatontown, New Jersey, United States
🇬🇧
Richmond Pharmacology Ltd (RPL), London, United Kingdom

Evaluation of Safety, Tolerability, and Efficacy of INZ-701 in Adults With ENPP1 Deficiency

Phase 1

Completed

Conditions: Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency
Autosomal Recessive Hypophosphatemic Rickets
Generalized Arterial Calcification of Infancy

Interventions: Drug: INZ-701

First Posted Date: 2020-12-28

Last Posted Date: 2025-02-05

Lead Sponsor: Inozyme Pharma

Target Recruit Count: 9

Registration Number: NCT04686175

Locations: 🇩🇪
Parexel International GmbH, Berlin, Germany
🇫🇷
Necker University Hospital-Sick Children, Paris, France
🇨🇦
University of Saskatchewan, Saskatoon, Saskatchewan, Canada

and more 4 locations

Understanding the Spectrum of ENPP1 Deficiency and Acute ABCC6 Deficiency

Completed

Conditions: Generalized Arterial Calcification in Infancy
Autosomal Recessive Hypophosphatemic Rickets Type 2

First Posted Date: 2020-05-04

Last Posted Date: 2021-04-01

Lead Sponsor: Inozyme Pharma

Target Recruit Count: 38

Registration Number: NCT04372446

Locations: 🇺🇸
Engage Health, Eagan, Minnesota, United States

Prev
1
Next

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy